(Oslo, April 30, 2026) Aker BioMarine reports double-digit revenue growth and a 34 percent increase in adjusted EBITDA in the first quarter of 2026. The results were driven by record-high sales of Superba krill oil and continued solid cost control
The company reports revenue of 57.3 million USD in the first quarter of 2026; an increase of 13 percent compared to the same period last year. Adjusted EBITDA increased by 34 percent to 12.5 million USD.
“The first quarter marks the highest-ever sales of Superba krill oil, reflecting strong underlying demand across our customer base. Krill oil sales grew 26 percent from the previous year, driven by both higher volumes and an improved price mix. “We have now delivered three consecutive years of quarterly growth in krill oil sales,” says the company’s CEO, Matts Johansen.
Financial performance in the first quarter
- Revenue: 57,3 million USD, up 13% from Q1 2025
- Adjusted EBITDA: 12.5 million USD, up 34% from Q1 2025
Record sales and improved margins
Human Health Ingredients (HHI) delivered revenue growth of 22 percent to 31.8 million USD, driven by strong demand across markets. Sales of Superbra krill oil alone reached USD 29.3 million, an increase of 26 percent.
Increased volumes and an improved price mix contributed to 27 percent EBITDA growth.
Consumer Health Products (CHP) reported revenue of 28.1 million USD, a 2 percent decline compared with the previous year. Starting in the first quarter of 2026, the segment includes both Lang and Epion/Kori. Lang grew moderately across most categories, while Epion is undergoing a market repositioning that is weighing on short-term sales but is expected to be positive over time. Profitability nevertheless improved, driven by lower sales and administrative costs
Outlook and strategic Direction
Human Health Ingredients is expected to maintain strong growth through 2026, supported by solid demand in several key markets. Consumer Health Products is expected to return to moderate growth. The sale process for Understory is still ongoing with several interested parties.
Following interest from the Human Health Ingredients business area, Aker BioMarine has engaged Jeffries & Hulihan Lokey as investment banks to explore strategic alternatives, with the goal of working toward a transaction in 2026